Intravenous Immunoglobulin a Natural Regulator of Immunity and Inflammation
- 15 July 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 88 (1), 1-6
- https://doi.org/10.1097/tp.0b013e3181a9e89a
Abstract
Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 25 years. IVIG products are also effective in the treatment of autoimmune and inflammatory disorders; however, the precise mechanism(s) of action is not known. Recent investigations suggest that IVIG has a much broader ability to regulate cellular immunity including innate and adaptive components. IVIG is also a recently recognized modifier of complement activation and injury. Here, we discuss these important advancements and how this knowledge applies to desensitization protocols and to the treatment of antibody-mediated rejection.Keywords
This publication has 45 references indexed in Scilit:
- Modulation of the cellular immune system by intravenous immunoglobulinTrends in Immunology, 2008
- The Antiinflammatory IgGThe New England Journal of Medicine, 2008
- Advances in the understanding of the mechanism of action of IVIgZeitschrift für Neurologie, 2008
- Anti-Inflammatory Actions of Intravenous ImmunoglobulinAnnual Review of Immunology, 2008
- Protective mechanisms of IVIGCurrent Opinion in Immunology, 2007
- Common variable immune deficiency and autoimmunityAutoimmunity Reviews, 2006
- Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal DiseaseJournal of the American Society of Nephrology, 2004
- REVERSAL OF STEROID- AND ANTI-LYMPHOCYTE ANTIBODY- RESISTANT REJECTION USING INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN RENAL TRANSPLANT RECIPIENTSTransplantation, 2001
- A RANDOMIZED AND PROSPECTIVE STUDY COMPARING TREATMENT WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN WITH MONOCLONAL ANTIBODIES FOR RESCUE OF KIDNEY GRAFTS WITH STEROID-RESISTANT REJECTIONTransplantation, 2001
- POSTTRANSPLANT THERAPY USING HIGH-DOSE HUMAN IMMUNOGLOBULIN (INTRAVENOUS GAMMAGLOBULIN) TO CONTROL ACUTE HUMORAL REJECTION IN RENAL AND CARDIAC ALLOGRAFT RECIPIENTS AND POTENTIAL MECHANISM OF ACTION1Transplantation, 1998